Spencer Pharmaceutical Amends Agreement With IAB Media Inc.

Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today that it has amended its agreement with IAB Media Inc. and reduced its compensation.

According to the company, IAB Media Inc. signed a service agreement on December 16, 2009 to provide Investor Relations and to manage the securities awareness campaign. The IAB Media compensation was established at 24 million shares and has now been reduced to 4 million shares, whereby IAB Media has returned to treasury 20 million shares.

"The compensation agreed upon in December of last year did not reflect the extent of the work being performed and we are truly grateful that the people at IAB Media also realized the discrepancy and have agreed to the reduced compensation," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "The work performed by the IAB Media team is important to the company and their professionalism is truly remarkable," further added Dr. Arella.

Takeda, Envoy Therapeutics In Schizophrenia Research Tie

Takeda Pharmaceutical Co. Ltd. (4502.TO) said Friday it and Envoy Therapeutics Inc. of the U.S. have formed a three-year alliance for discovering new schizophrenia drugs.

Takeda, Japan's largest pharmaceutical company by sales, will make an upfront payment of $3 million and shoulder $2.25 million a year of their joint research cost, they said in a joint statement.

The Japanese drug maker will also pay milestone and royalty fees to the Florida-based company when they successfully develop and commercialize one or more schizophrenia treatments.

Their agreement is aimed at developing a better and safer drug for schizophrenia, a chronic brain disorder affecting more than 20 million people worldwide.

Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it had signed an agreement with iMedicor (OTC Bulletin Board: VMCI) for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy. Using iMedicor's highly targeted Alerts System application, initial introduction of MuGard to the 216,000 selected physicians in the US is expected to begin by the end of the year. MuGard is being commercially launched worldwide, with initial launches in the United Kingdom, Germany, Italy, Norway and Greece having been previously announced. Access expects additional commercial launches in Europe, and in the Far East through two partners to start shortly.

"We look forward to working with Access Pharma to help them introduce MuGard in a cost effective, non-intrusive manner, a potential blockbuster product which could significantly improve the quality of life for patients undergoing certain cancer treatments," said Fred Zolla, CEO of Vemics iMedicor. "Using our Alert System, iMedicor's ability to deliver essential information from a trusted source to specific physician audiences will significantly increase our client's marketing ROI."

MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 80% of all patients receiving radiotherapy and approximately 40% of all chemotherapy patients develop oral mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion world-wide.

"We are excited about iMedicor's ability to introduce MuGard more rapidly and to a broad physician audience than we would expect through traditional distribution channels," said Access' CEO Jeffrey Davis. "We believe through this new marketing partnership with iMedicor, Access will be able to reach a broad spectrum of oncologists, radiation oncologists and other key clinicians in a very cost-effective manner, to utilize the medical education aspects of the system to educate about oral mucositis and MuGard, and to accelerate commercial uptake in the US market."